Overview

Adipose Dysfunction, Imaging, Physiology, and Outcomes With Sodium Glucose Cotransporter 2 Inhibitor (SGLT2i) for Sleep Apnea: The ADIPOSA Study

Status:
Not yet recruiting

Trial end date:
2027-09-01

Target enrollment:

Participant gender:

Summary

The goal of this clinical trial is to test if ertugliflozin lowers the sleep apnea severity in adults who are overweight or obese with moderate to severe obstructive sleep apnea (OSA) compared with a placebo (look-alike substance that contains no active drug). The main question it aims to answer is: - If SGLT2i will reduce anatomic and physiologic traits, clinical measures of OSA and sleep deficiency in participants - If improvement in clinical measures are because of improvement in the anatomic and physiologic traits. Participants will be placed on either drug or placebo and get routine normal care for 6 months. At the start and end of the study, participants will undergo different clinical measurements to see if the drug makes the sleep apnea better.

Phase:

Phase 4

Details

Lead Sponsor:

Yale University

Collaborator:

Case Western Reserve University

Treatments:

Ertugliflozin